RecruitingPhase 3

Sotagliflozin to Slow Kidney Function Decline in Persons With Type 1 Diabetes and Diabetic Kidney Disease

NCT06217302

What is this trial?

Generating plain-language summary...

Generating eligibility summary...

Summarizing study design...

Primary location

Stanford University Medical Center

Stanford, California, United States

+18 additional locations

Contact

Christine Mendonca

Save this trial

Stanford University Medical CenterStanford, California, United States
Barbara Davis Center / University of Colorado DenverAurora, Colorado, United States
AdventHealthOrlando, Florida, United States
Northwestern University Feinberg School of MedicineChicago, Illinois, United States
Joslin Diabetes CenterBoston, Massachusetts, United States
Washington UniversitySt Louis, Missouri, United States
SUNY Upstate Medical UniversitySyracuse, New York, United States
Albert Einstein College of Medicine / Montefiore Medical CenterThe Bronx, New York, United States
Cleveland Clinic FoundationCleveland, Ohio, United States
Oregon Health and Science UniversityPortland, Oregon, United States
University of Texas SouthwesternDallas, Texas, United States
University of WashingtonSeattle, Washington, United States
Providence Sacred Heart Medical CenterSpokane, Washington, United States
Unversity of CalgaryCalgary, Alberta, Canada
Alberta Diabetes InstituteEdmonton, Alberta, Canada
St. Paul's HospitalVancouver, British Columbia, Canada
LMC Diabetes and EndocrinologyToronto, Ontario, Canada
Toronto General HospitalToronto, Ontario, Canada
Institut de Recherches Cliniques de MontréalMontreal, Quebec, Canada